Resultado de búsqueda
Katherine A. High is an American doctor-scientist who is an emeritus professor at the Perelman School of Medicine at the University of Pennsylvania. She was the co-founder, president, and chief scientific officer of Spark Therapeutics and currently serves as President of Therapeutics at AskBio.
- Gene Therapy
- Hematology
- American
27 de oct. de 2016 · Katherine A. High, M.D. Emeritus Professor of Pediatrics (Hematology) Attending Physician, The Children's Hospital of Philadelphia. Attending Physician, Hospital of the University of Pennsylvania. Attending Physician, Presbyterian Hospital Medical Center.
27 de oct. de 2016 · Dr. High, a world renowned hematologist, studies the molecular basis of blood coagulation and the development of novel therapeutics for the treatment of bleeding disorders. Her pioneering bench-to-bedside studies of gene therapy for hemophilia have led to a focus on clinical translation of genetic therapies for hemophilia and other ...
15 de mar. de 2017 · Katherine A. High is Emeritus Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania. A renowned hematologist, her research group pioneered safe and effective clinical translation of genetic therapies for inherited disorders.
Katherine A. High is a distinguished physician-scientist and currently a Visiting Professor at Rockefeller University. She is also Professor Emerita at the Perelman School of Medicine at the University of Pennsylvania and previously served as President of Therapeutics at AskBio.
4 de abr. de 2023 · Physician-scientist and gene therapy pioneer, Dr. Katherine High, had a long career as an academic hematologist studying hemophilias and gene therapy vectors, before moving into industry. In both realms, High ( Figure 1 ) played a massive role in bringing forward the first FDA-approved gene therapy.
6 de may. de 2021 · AskBio. Dr. Katherine High trained in internal medicine, hematology, and molecular genetics. Her pioneering bench-to-bedside studies of gene therapy for hemophilia led to a series of basic and clinical investigations that characterized the human immune response to AAV gene delivery vectors.
